USPTO serial 79121914
FINES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 21, 2013
- Examiner
- MICHOS, JOHN E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with FINES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Boehringer Ingelheim Pharma GmbH & Co. KG
DE
Other trademarks owned by Boehringer Ingelheim Pharma GmbH & Co. KG
Boehringer Ingelheim Pharma; GmbH & Co. KG
DE
Other trademarks owned by Boehringer Ingelheim Pharma; GmbH & Co. KG
Boehringer Ingelheim Pharma; GmbH & Co. KG
DE
Other trademarks owned by Boehringer Ingelheim Pharma; GmbH & Co. KG
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 041 | Publication of printed matter with the results of clinical studies, namely studies with topical anti-rheumatics and analgetics in the treatment of rheumatic diseases and stimulating skin circulation involving musculoskeletal disorders (including in electronic form) | SECTION 71 - CANCELLED | — |
| 042 | Conducting of clinical studies with topical anti-rheumatics and analgetics in the treatment of rheumatic diseases and stimulating skin circulation involving musculoskeletal disorders | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Boehringer Ingelheim Pharma GmbH & Co. KG
- Other trademarks owned by Boehringer Ingelheim Pharma; GmbH & Co. KG
- Other trademarks owned by Boehringer Ingelheim Pharma; GmbH & Co. KG
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named FINES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 22, 2023 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Apr 22, 2023 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Oct 24, 2020 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 26, 2020 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Sep 26, 2020 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Aug 27, 2020 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Dec 27, 2019 | C71T | CANCELLED SECTION 71 | — |
| Jul 13, 2013 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 20, 2013 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 20, 2013 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 20, 2013 | GPAR | GRANT OF PROTECTION CREATED, TO BE SENT TO IB | — |
| May 21, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 6, 2013 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 5, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 27, 2013 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 27, 2013 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 13, 2013 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 28, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 23, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 1, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 28, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 20, 2012 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |